Results 151 to 160 of about 255,779 (244)

Flow cytometric phenotyping of diverse human cancer cell lines for immunological biomarkers expression [PDF]

The tumour microenvironment contains a variety of distinct factors that inhibit the immune system and can cause drug resistance. Some of these factors include the expression of cell surface markers which interact directly with immune cells.
Cross, Neil, Hudson, Katie, Jordan-mahy, Nicola, Leyland, Rebecca   +3 more
core  

Engineering MnPt Bimetallic Nanozymes for Cascade Enzymatic Therapy and Enhanced Radio‐Immunotherapy

Advanced Science, EarlyView.
A CD44‐targeted MnPt bimetallic nanozyme (HD@MnO2) integrates multienzyme‐like activity with cGAS–STING activation to boost radio‐immunotherapy. Through cascade biocatalysis, it depletes glutathione, relieves hypoxia, and amplifies ROS, enhancing radiotherapy‐induced DNA damage and immunogenic cell death. The nanozyme promotes dendritic cell maturation
Wenyi Zhang, Yangyang Guo, Guoping Xu, Luhaoxiang Liu, Lin Chen, Cai Zhang, Yiming Li, Jianmin Li, Yang Zhao   +8 more
wiley   +1 more source

Strategies to target PD-1/PD-L1 in the tumor microenvironment. [PDF]

Cell Oncol (Dordr)
Kui Y, Tong F, Zhang R, Dong X, Wang J.
europepmc   +1 more source

Immunomodulatory Fibrous Scaffold with Dual Enzyme‐Mimic Activities Prevents Postsurgical Tumor Recurrence

Advanced Science, EarlyView.
A MnOx nanozyme‐functionalized electrospun fibrous scaffold is developed for postoperative therapy by leveraging its intrinsic physicochemical and immunomodulatory properties. Integrating POD‐ and CAT‐like activities, the scaffold induces immunogenic cell death, alleviates hypoxia, and reverses immunosuppression, while simultaneously recruiting and ...
Xiaoyi Zhao, Zhuolong Jiao, Yue Wang, Huimeng Gu, Longfei Li, Jian Song, Chen Xu, Jiajia Xue, Fu‐Jian Xu, Nana Zhao   +9 more
wiley   +1 more source

Clinical Benefit of PD-1/PD-L1 Inhibitors as Standard First-Line Treatment in Low PD-L1-Expressing Advanced Solid Tumors: A Systematic Review and Meta-Analysis. [PDF]

MedComm (2020)
Wu P, Gu X, Li D, Zi X, Shang D, Liu J, Ma R, Peng J, Zhang G, Che Y, Zeng Q, Zhao B, Sun N, Zhang C, He J.   +14 more
europepmc   +1 more source

CD3ɛ Nanobody‐Engineered Extracellular Vesicles Driving In Vivo Generation of TCE‐secreting CAR‐Ts for Solid Tumor Therapy With Memory Response and Minimal Immunogenicity

Advanced Science, EarlyView.
HEK‐293T‐derived CD3ε Nb‐engineered EVs to generate dual‐targeting CAR‐T cells directly in vivo. These EVs selectively deliver CAR.BiTE transgenes into T cells and reprogramed to HLA‐G/PD‐L1‐targeting effector cells with enhanced memory and persistence.
Shi‐Wei Huang, Yu‐Chuan Lin, Chih‐Ming Pan, Yeh Chen, Ming‐You Shie, Cheng‐Yu Chen, Kai‐Wen Kan, Yi‐Wen Chen, Ming‐Chao Liu, Chung‐Chun Wu, Yu‐Ting Chiang, Huai‐Ping Ho, Chen‐Yu Lin, Pei‐Ying Lin, Yu‐Han Huang, Steffany Rusli, Wan‐Yu Mao, Pei‐Wen Huang, Sin‐Ting Wang, Wan‐Chen Tsai, Ya‐Hsu Chiu, Ting‐Hsun Lin, Wan‐Ling Chiang, Che‐Kai Chang, Zi‐Lun Lai, Mei‐Chih Chen, Shao‐Chih Chiu, Der‐Yang Cho   +27 more
wiley   +1 more source

The role of PD‑1/PD‑L1 axis in liver diseases. [PDF]

Clin Exp Med
Zeng Z, Chen S, Niu Q, Dong H, Yao Y, Wang K, Gong X, Li H.   +7 more
europepmc   +1 more source

PD‐L1‐Binding Antigen Presenters: Redirecting Vaccine‐Induced Antibodies for Cancer Immunotherapy

Advanced Science, EarlyView.
The PBAP‐gE complex anchors gE antigen to PD‐L1 on tumor cells. Vaccine‐induced anti‐gE antibodies simultaneously engage FcγRIIIa on NK cells and tumor‐bound PBAP‐gE, triggering NK cell activation and antibody‐dependent cellular cytotoxicity, thereby selectively eliminating PD‐L1–expressing tumor cells.
Huixin Gao, Lijuan Lu, Xiaoxiao Xiong, Yi Li, Donghui Hu, Duo Zhang, Zhiwei Feng, Cong Liu, Nannan Liu, Xiaoli Li, Jizhou Tan, Ting Liu, Ling Peng, Lu Lu, Huiyi Feng, Yan Zhong, Guisen Tan, Zhicheng Zhang, Liqin Huang, Chao Su, Ying Xue, Shuo Song, Wenxia Fan, Wei Wang, Fan Zou   +24 more
wiley   +1 more source

Cellular Identity Crisis: RD3 Loss Fuels Plasticity and Immune Silence in Progressive Neuroblastoma

Advanced Science, EarlyView.
Researchers discovered that therapy‐induced loss of RD3 protein in neuroblastoma triggers a dangerous shift: cancer cells become more stem‐like, invasive, and resistant to treatment while evading immune detection. RD3 loss suppresses antigen presentation and boosts immune checkpoints, creating an immune‐silent environment.
Poorvi Subramanian, Sreenidhi Mohanvelu, Sheeja Aravindan, Afsana Parveen Jahir Hussain, Sivasubramani Narayanan, Sabir Salim, Loganayaki Periyasamy, Natarajan Aravindan   +7 more
wiley   +1 more source

Best Practice PD-L1 Staining and Interpretation in Gastric Cancer Using PD-L1 IHC PharmDx 22C3 and PD-L1 IHC PharmDx 28-8 Assays, with Reference to Common Issues and Solutions. [PDF]

Biomedicines
Ahn S, Hwang I, Kim Y, Lee S, Cho Y, Kang SY, Kim DG, Lee J, Kim KM.   +8 more
europepmc   +1 more source